Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia

(MedPage Today) -- SAN DIEGO -- Nearly two-thirds of patients with relapsed or refractory KMT2A-rearranged acute leukemia responded to an investigational oral menin inhibitor, a phase II trial showed. Among 57 children and adults in the pivotal...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news